RNAC

Harvard Professor Buys $12 Million of Cartesian Therapeutics ($RNAC) Stock Despite 70% Plunge - Insider Conviction Amid Promising Clinical Results

04/11/2025 21:48

Timothy A. Springer, director at Cartesian Therapeutics Inc ($RNAC), has been aggressively purchasing company stock despite recent market tumbles, drawing significant investor attention. Springer, a renowned immunologist and Harvard Medical School professor, acquired approximately $1.5 million worth of $RNAC shares in just three days from April 9-11, 2025. According to SEC filings, he purchased 49,155 shares ($476,245) on April 9, followed by 57,170 shares ($610,507) on April 10, and 42,750 shares ($460,528) on April 11. These acquisitions, at average prices ranging from $9.69 to $10.77 per share, demonstrate unwavering confidence amid market volatility triggered by President Trump's tariff policy announcements. This recent buying spree continues Springer's pattern of substantial investments in $RNAC. Since early October 2024, he has invested over $12 million in the company's stock. Notably, when share prices declined in March 2025, he acquired an additional 89,863 shares (approximately $1.37 million), and in November 2024, he executed a massive $7.4 million purchase within just five days. Springer's bullish stance aligns with Cartesian's recent positive clinical developments. On April 8, 2025, the company announced that its flagship product, Descartes-08, demonstrated significant and sustained benefits for myasthenia gravis patients lasting up to 12 months following a single treatment course in its Phase 2b clinical trial. Based on these promising results, Cartesian plans to initiate the Phase 3 Aurora trial in the second quarter of 2025. However, contrasting with Springer's optimistic outlook, several executives, including CTO Metin Kurtoglu, have been selling shares over recent months. Kurtoglu sold shares on multiple occasions between November 2024 and January 2025, while other executives including CFO Blaine Davis and President Carsten Brunn also divested portions of their holdings. Some of these sales were reportedly executed to satisfy tax obligations. $RNAC's stock has experienced significant volatility, plummeting approximately 70% from around $36 in June 2024 to just over $10 currently. This decline reflects both broader biotech sector weakness and recent market uncertainties. Financially, Cartesian maintains a relatively stable position with $212.61 million in cash reserves and modest debt of $13.98 million. Its current ratio stands at an impressive 9.43, substantially exceeding industry averages. However, the company continues to operate at a loss, reporting an annual net loss of $77.42 million. Wall Street analysts maintain an average "Buy" rating on $RNAC, with a median price target of $41.00, suggesting substantial upside potential from current levels. The promising clinical results for Descartes-08 could serve as a potential catalyst for share price recovery if commercialization prospects improve. Springer's background adds significant weight to his investment decisions. As a Harvard Medical School professor and immunology pioneer, he has a track record of successful biotech ventures, including founding LeukoSite and early investments in Moderna. His consistent large-scale purchases signal strong conviction in Cartesian's technology and future value. Looking ahead, key milestones for $RNAC include the commencement of the Phase 3 Aurora trial in Q2 2025 and ongoing developments regarding Descartes-08's commercialization potential. Investors will also be watching closely to see if Springer continues his extraordinary buying pattern in the coming months.

You can receive notifications when news is published.